TICKERNOMICS Sign up
Last Update: 2024-03-28 02:14:57
CytoMed Therapeutics Ltd ( GDTC )
2.13USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
GDTC
0.00%
SPY
32.74%
GDTC
0.00%
SPY
92.93%
GDTC
0.00%
SPY
224.41%
GDTC
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
41.16
45.92
0.00
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
0.00
0.00
94.12
0.00
0.00
0.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
0.00
0.00
0.00
Other Earnings and Cash Flow Stats:
CytoMed Therapeutics Ltd ( GDTC ) Net Income TTM ($MM) is 0.00
CytoMed Therapeutics Ltd ( GDTC ) Operating Income TTM ($MM) is 0.00
CytoMed Therapeutics Ltd ( GDTC ) Owners' Earnings Annual ($MM) is 0.00
CytoMed Therapeutics Ltd ( GDTC ) Current Price to Owners' Earnings ratio is 0.00
CytoMed Therapeutics Ltd ( GDTC ) EBITDA TTM ($MM) is 0.00
CytoMed Therapeutics Ltd ( GDTC ) EBITDA Margin is 0.00%
Capital Allocation:
CytoMed Therapeutics Ltd ( GDTC ) has paid 0.00 dividends per share and bought back 7.915101 million shares in the past 12 months
CytoMed Therapeutics Ltd ( GDTC ) has reduced its debt by 5.9393867138462 million USD in the last 12 months
Capital Structure:
CytoMed Therapeutics Ltd ( GDTC ) Interest-bearing Debt ($MM) as of last quarter is 0
CytoMed Therapeutics Ltd ( GDTC ) Annual Working Capital Investments ($MM) are 0
CytoMed Therapeutics Ltd ( GDTC ) Book Value ($MM) as of last quarter is 0
CytoMed Therapeutics Ltd ( GDTC ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
CytoMed Therapeutics Ltd ( GDTC ) has 0 million in cash on hand as of last quarter
CytoMed Therapeutics Ltd ( GDTC ) has 0 million of liabilities due within 12 months, and long term debt 0 as of last quarter
CytoMed Therapeutics Ltd ( GDTC ) has 0 common shares outstanding as of last quarter
CytoMed Therapeutics Ltd ( GDTC ) has 0 million USD of preferred stock value
Academic Scores:
CytoMed Therapeutics Ltd ( GDTC ) Altman Z-Score is 0.00 as of last quarter
CytoMed Therapeutics Ltd ( GDTC ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
CytoMed Therapeutics Ltd ( GDTC ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of CytoMed Therapeutics Ltd ( GDTC ) for the amount of $ on
0.00% of CytoMed Therapeutics Ltd ( GDTC ) is held by insiders, and 0.00% is held by institutions
CytoMed Therapeutics Ltd ( GDTC ) went public on 2023-04-14
Other CytoMed Therapeutics Ltd ( GDTC ) financial metrics:
FCF:0.00
Unlevered Free Cash Flow:0.00
EPS:0.00
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:0.00
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About CytoMed Therapeutics Ltd ( GDTC ) :
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.